Form 4: Neogenomics Director Tetrault Reports Stock Transactions

Director Lynn A. Tetrault of Neogenomics Inc. has reported transactions involving common stock and stock options, indicating a shift in beneficial ownership.

Summary

• Director Lynn A. Tetrault of Neogenomics Inc. has reported a transaction involving the disposal of 5,307 shares of common stock at a price of $11.10 per share on June 15, 2026.
• Following this transaction, Tetrault beneficially owns 86,115 shares of common stock directly.
• Additionally, Tetrault holds 7,000 shares indirectly through the Lynn Tetrault Rollover IRA.
• The filing also details various stock options held by Tetrault, with exercise prices ranging from $7.28 to $41.76, and corresponding underlying common stock amounts.
• A Restricted Stock Unit (RSU) for 15,970 shares of common stock, granted on June 1, 2027, is also noted.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions without providing new financial or strategic information about the company.

Positives

• Director Lynn A. Tetrault continues to hold a significant number of shares and stock options in Neogenomics Inc., indicating ongoing commitment.
• The disposal of shares at $11.10 per share suggests a potential realization of gains or strategic portfolio management by the director.

Negatives

• The disposal of 5,307 shares of common stock by a director could be interpreted as a reduction in direct ownership, though the overall beneficial ownership remains substantial.

Risks

• The exercise prices of some stock options are significantly higher than the recent transaction price ($11.10), suggesting they are currently out-of-the-money.
• The value of outstanding stock options is subject to market fluctuations and the company's future stock performance.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not inherently signal company performance. The reported transactions by Director Tetrault are typical for executive compensation and portfolio management within the biotechnology sector.

Stakeholder Impact

• Shareholders: The disposal of shares by a director may be observed, but without further context, its impact on share price is uncertain. The continued holding of significant equity and options by the director suggests confidence.

Key Dates

Keywords

Neogenomics Inc., NEO, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Beneficial Ownership, Director Transactions, Lynn A. Tetrault